Logo of Recce Pharmaceuticals (ASX:RCE)Latest Recce Pharmaceuticals (ASX:RCE) News

Page 4
Page 4 of 5

Recce Advances Phase 3 Trial and Secures $85M R&D Funding Eligibility

Recce Pharmaceuticals progresses its Phase 3 diabetic foot infection trial in Indonesia, reports promising preclinical data for inhaled RECCE 327, and secures significant R&D funding and patent protection.
Ada Torres
30 Jan 2026

Recce Pharmaceuticals Secures $5.3m R&D Rebate to Boost Anti-Infective Trials

Recce Pharmaceuticals has received a $5.3 million R&D tax rebate from the Australian Taxation Office, providing a significant cash injection to support its innovative synthetic anti-infective drug development programs.
Ada Torres
14 Jan 2026

Recce Pharmaceuticals Secures A$85M R&D Tax Incentive Boost for Global Antibiotic Fight

Recce Pharmaceuticals has won a significant Australian Government R&D tax incentive, unlocking up to A$85 million for its synthetic anti-infective programs worldwide, including a pivotal Phase 3 clinical trial.
Ada Torres
16 Dec 2025

Recce Pharmaceuticals Expands Asian Patent Reach with Hong Kong Approval

Recce Pharmaceuticals has secured a key patent in Hong Kong for its synthetic anti-infectives, reinforcing its intellectual property footprint in Asia and supporting its clinical and commercial ambitions in the region.
Ada Torres
27 Nov 2025

Recce’s Inhaled RECCE 327 Slashes Drug-Resistant Pneumonia in Preclinical Tests

Recce Pharmaceuticals has reported compelling preclinical results for its inhaled anti-infective RECCE 327, demonstrating potent activity against multidrug-resistant pneumonia bacteria in mice models.
Ada Torres
26 Nov 2025

Recce Pharmaceuticals Advances Phase 3 Trial Amid Strong Antibacterial Data

Recce Pharmaceuticals has commenced patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, supported by promising antibacterial efficacy data and extended funding arrangements.
Ada Torres
31 Oct 2025

Recce Pharmaceuticals Advances Phase 3 Trial for Diabetic Foot Infection Treatment in Indonesia

Recce Pharmaceuticals has initiated patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, targeting a significant market with high diabetes prevalence. Interim results expected in early 2026 could accelerate regulatory approval and commercial launch.
Ada Torres
25 Sept 2025

Recce Pharmaceuticals Advances Phase 3 Trials Amid Rising Losses

Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.
Ada Torres
29 Aug 2025

Recce’s RECCE 327 Gel Accelerates Healing in Drug-Resistant Burn Wounds

Recce Pharmaceuticals’ RECCE 327 Topical Gel shows statistically significant superiority over standard antibiotics in treating antibiotic-resistant burn wounds in preclinical models, advancing its U.S. Department of Defense collaboration.
Ada Torres
12 Aug 2025

Recce Pharmaceuticals Secures $15.8M Capital Raise Amid Phase 3 Trial Expansion

Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.
Ada Torres
31 July 2025

Recce Pharmaceuticals Secures A$30M Debt Facility to Fuel Phase 3 Trials and Market Launch

Recce Pharmaceuticals has locked in a non-dilutive A$30 million debt facility with Avenue Capital Group, extending its cash runway to support pivotal Phase 3 trials and commercialisation of its synthetic anti-infective R327G.
Ada Torres
17 June 2025

Recce Pharmaceuticals Secures A$15.8M to Advance Critical Phase 3 Trials

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.
Ada Torres
3 June 2025